Headaches have hundreds of potential causes and are one of the more painful common conditions that bring patients to primary care physicians and neurologists. Migraine headache affects about 29.5 million people in the United States. You can get to know more about botulinum toxin via visiting www.clinique-suisse.com/fr/medecine-chirurgie-esthetique/medecine-esthetique/botox.
Women are three times more likely to suffer from them than men. They are more common among older people between 20 and 45 years and is a major cause of work absenteeism and reduced work productivity. Direct and indirect costs of migraine in the economy an estimated $ 50 billion per year.
Using injections of botulinum toxin is a controversial treatment to prevent migraine headaches. Reports in the scientific literature (including a retrospective case series, uncontrolled studies and nonblinded, small controlled trials and case reports) suggest botulinum reduce migraines in some patients.
However, recently some of the larger and randomized, double-blind, a placebo-controlled clinical trial is designed not to support different botulinum toxin as a treatment. A clinical trial entitled "Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Headache Sufferers often" is currently underway.
Physicians considering botulinum toxin therapy for migraine patients must take a thorough review of the patient's clinical history; perform a physical examination in depth; conducting or reviewing the diagnostic studies; consider treatment in the past and the present and the patient's response to them, and consider any disease or co-morbid conditions.
Until the results of clinical trials of current and future botulinum toxin for the prevention of migraine headaches can give a definite answer about the efficacy and safety, physicians should use it on a case-by-case basis. The only individual approach allows the physician to balance all the considerations when using botulinum toxin.